XKRX241820
Market cap4mUSD
Dec 20, Last price
582.00KRW
1D
-4.75%
1Q
-52.80%
IPO
-79.43%
Name
PCL Inc
Chart & Performance
P/E
—
P/S
0.83
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.21%
Rev. gr., 5y
130.86%
Revenues
8.43b
-77.35%
Net income
-20.32b
L+405.73%
CFO
-4.92b
L+394.11%
Profile
PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers multiplex antibody and antigen diagnostic kits for the detection of antibodies to human immunodeficiency virus (HIV) 1 and 2, HBV, hepatitis C virus (HCV), and human T-lymphotropic virus 1 and 2, as well as antigens to HIV p24, HCV core, and HBV surface in human serum or plasma. It also provides Ai, an influenza A/B typing rapid diagnostic test kit; Cancer6, a multiple tumor markers screening kit; and sciLINER LATERAL FLOW DISPENSER, a dispenser for membrane materials with active visual drop volume control. In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified. PCL, Inc. is headquartered in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 8,429,532 -77.35% | 37,217,227 -19.35% | 46,147,522 -14.04% | ||||||
Cost of revenue | 17,670,167 | 43,240,152 | 68,762,974 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (9,240,635) | (6,022,925) | (22,615,453) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (81,441) | 6,312 | (2,903) | ||||||
Tax Rate | |||||||||
NOPAT | (9,159,194) | (6,029,238) | (22,612,549) | ||||||
Net income | (20,317,924) 405.73% | (4,017,548) -87.31% | (31,669,319) -262.33% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 23,305,425 | 12,271,607 | 3,175,084 | ||||||
BB yield | -16.01% | -6.95% | -0.79% | ||||||
| Debt | |||||||||
Debt current | 15,634,422 | 25,976,612 | 18,451,009 | ||||||
Long-term debt | 4,084,446 | 5,205,583 | 15,457,928 | ||||||
Deferred revenue | 10 | ||||||||
Other long-term liabilities | 552,813 | 1,208,776 | 1,036,127 | ||||||
Net debt | (11,510,889) | (14,285,454) | (4,815,231) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (4,916,651) | (995,050) | (16,224,740) | ||||||
CAPEX | (3,259,165) | (2,808,174) | (8,690,310) | ||||||
Cash from investing activities | (3,844,938) | (20,905,892) | (7,107,810) | ||||||
Cash from financing activities | (10,364,074) | 9,238,752 | 57,060,128 | ||||||
FCF | (15,137,438) | (10,460,368) | (789,903) | ||||||
| Balance | |||||||||
Cash | 11,802,825 | 32,467,651 | 38,224,168 | ||||||
Long term investments | 19,426,932 | 12,999,998 | 500,000 | ||||||
Excess cash | 30,808,281 | 43,606,788 | 36,416,792 | ||||||
Stockholders' equity | (31,964,155) | (30,993,796) | (23,950,000) | ||||||
Invested Capital | 89,408,106 | 96,617,803 | 75,429,408 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 40,615 | 35,429 | 34,054 | ||||||
Price | 3,585.00 -28.06% | 4,983.33 -57.95% | 11,850.00 -2.74% | ||||||
Market cap | 145,605,083 -17.53% | 176,552,380 -56.25% | 403,545,576 -2.68% | ||||||
EV | 136,214,151 | 164,352,835 | 404,677,118 | ||||||
EBITDA | (6,375,274) | (3,436,895) | (20,583,267) | ||||||
EV/EBITDA | |||||||||
Interest | 2,496,338 | 4,220,249 | 2,980,631 | ||||||
Interest/NOPBT | |||||||||